free iso 9001 training full

BioHarvest Sciences New 20 Tons Per Year Factory Successfully Passes the ISO9001 and ISO22000 Audit

BioHarvest Sciences Inc. ("BioHarvest" or the "Company") (CSE: BHSC) announces that the new manufacturing facility in Israel has successfully met the Israeli Ministry of Health's ISO9001 and ISO22000 (HACCP) certification requirements ahead of time. The ISO9001 certification covers internationally recognized standards for quality assurance and management, and the ISO22000 (HACCP) certification ensures that the required quality control and quality management systems are in place across the end-to-end manufacturing process to ensure the highest product safety levels. These 2 certifications are critical steps required prior to obtaining the GMP (Good Manufacturing Practices) certification from the Israeli Ministry of Health.

(PRNewsfoto/BioHarvest Sciences Inc.)

Despite the challenges caused by COVID19 to the global supply chain, this factory was built in 12 months. The facility will have the capacity to produce over 20 tons/year of VINIA® as well as other polyphenol-based products the Company has in its innovation pipeline. Pilot production of VINIA® in the new facility is expected to begin by the end of September 2021 , and the capacity will be steadily increased each month to meet the growing demands of VINIA®'s D2C and B2B business in Israel , USA , and other global markets.

Kobi Rosenzweig , VP of Operations at BioHarvest Sciences, said, " I am delighted with the Company's ability to successfully pass the internationally recognized   stringent quality requirements on its first attempt. Considering the speed at which this factory was built, this achievement is a testimony to the quality of the team and the ingenuity of the BioFarming technology. I thank our manufacturing partner Sugart and especially Ori Hahn , their CEO, for all the efforts exerted to deliver on such an aggressive schedule. "

" The manufacturing arm of BioHarvest is an integral part of the Company's biotech vision, " said Ilan Sobel , CEO of BioHarvest Sciences. " As a biotech innovator we will continue to develop and manufacture new products across multiple verticals. We have implemented the industrial manufacturing blueprint of our BioFarming technology in 12 months. This accomplishment gives me enormous confidence in our ability to scale our technology as we add on new verticals, (as in the case of Cannabis), and to build manufacturing plants closer to local markets such as North America , if required. "

About BioHarvest Sciences Inc. 
Based in Vancouver BC, BioHarvest Sciences Inc. is the developer and exclusive owner of the proprietary and patent-protected BioFarming technology. It is the first and only industrial-scale plant cell technology capable of producing the active plant ingredients without the necessity to grow the plant itself. The Company's technology is non-GMO and has already been validated by VINIA®, the red grapes cells functional food/dietary supplement produced and sold by BioHarvest Sciences Inc. The Company plans to generate significant revenue within the global nutraceutical ingredients and dietary supplements market with VINIA® and other Super Fruit Nutraceutical products. Further, by adapting this technology to the Cannabis plant, and building adequate production capacity, BioHarvest Sciences Inc.'s objective is to become a leading supplier of Cannabis for both medicinal and legal recreational purposes. Visit: www.bioharvest.com .

BioHarvest Sciences Inc.
Ilan Sobel , Chief Executive Officer

Forward-Looking Statements  
Information set forth in this news release includes might include forward-looking statements that are based on management's current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. In particular, there is no assurance the Company will be able to successfully convert the exiting 2 tons/year VINIA® facility to a Cannabis production facility in H1, 2022 and there is no guarantee that the new facility will begin production of VINIA® end of September 2021 . There is no assurance we will be able to commercialize our first Cannabis products in the first half of 2022 and there is no assurance the Company will be able to add new verticals or build additional plants elsewhere. Delays and cost overruns may result in delays achieving our objectives obtaining market acceptance and regulatory approvals for geographic expansion is subject to risk and cannot be guaranteed. The success of the Company in demonstrating its ability to consistently grow in solution trichomes from multiple plant strains is not an assurance that the Company will be able to commence commercial production when anticipated or at all. While the Company is in the process of constructing a two-ton production facility the Company   's current licensing only permits scientific research. Projected sales of Cannabis will require the Company to obtain production and or export licensing which cannot be assured.

All forward-looking statements are inherently uncertain and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHSC does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures.

Neither the Canadian Securities Exchange nor its Regulation Services Provider accept responsibility for the adequacy or accuracy of this release.

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/bioharvest-sciences-new-20-tons-per-year-factory-successfully-passes-the-iso9001-and-iso22000-haccp-audit-301372375.html

SOURCE BioHarvest Sciences Inc.

News Provided by PR Newswire via QuoteMedia

The Conversation (0)

AMGEN TO PRESENT DATA FROM MULTIPLE EARLY-STAGE CLINICAL TRIALS AT ESMO 2024

Results Illustrate Depth and Diversity of Amgen's Targeted Therapies Across Tumor Types

- Amgen (NASDAQ: AMGN) today announced the presentation of new data across its broad oncology pipeline and portfolio at the European Society for Medical Oncology (ESMO) Congress 2024, taking place Sept. 13-17 in Barcelona . The abstracts showcase data from Amgen-sponsored and investigator-sponsored studies for colorectal, lung, prostate and gastric cancers using molecularly targeted modalities.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

AMGEN PRESENTS NEW DATA FOR FIRST-IN-CLASS IMDELLTRA IN SMALL CELL LUNG CANCER AT WCLC 2024

DeLLphi-303 Study Results Show Potential for IMDELLTRA in Combination with a PD-L1 Inhibitor as First-Line Maintenance Therapy in ES-SCLC

DeLLphi-301 Long-Term Follow-up Data Demonstrate Sustained Safety and Efficacy for IMDELLTRA

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

AMGEN TO PRESENT AT THE 2024 WELLS FARGO HEALTHCARE CONFERENCE

Amgen (NASDAQ:AMGN) will present at the 2024 Wells Fargo Healthcare Conference at 9:30 a.m. ET on Thursday Sept. 5, 2024. Peter Griffith executive vice president and chief financial officer at Amgen, and Jay Bradner executive vice president of Research and Development and chief scientific officer at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.

The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com , under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
  BPH Global Ltd

Appendix 4E and Preliminary Final Report - For the Year Ended 30 June 2024

BPH Global Limited (ASX: BP8) (“BP8” or the “Company” or the “Group”) has released its Appendix 4E Preliminary Final Report.


Keep reading...Show less
Hydralyte

H1 FY24 Half Year Report and Appendix 4D: 29% Reduction in Net Cash Used in Operating Activities alongside Stable Revenue

Hydration solutions company The Hydration Pharmaceuticals Company Limited (ASX: HPC) (“Hydralyte North America” or “the Company”) is pleased to provide the following update on the six-month period ended 30 June 2024 (the “half year” or “H1 FY2024”) and the Company’s Appendix 4D.

Keep reading...Show less

Latest Press Releases

Related News

×